Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRISK: Bevacizumab plus erlotinib for advanced cancers with Krebs cycle genetic alterations
KCT0007840Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Jan 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, erlotinib in cancer, sponsored by Boryung. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
bevacizumaberlotinib
03
Conditions
cancer
Beyond the preview
Go deeper on KCT0007840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007840.